Medical Editor: John P. Cunha, DO, FACOEP
Nimbex (cisatracurium besylate) is a skeletal muscle relaxant given before general anesthesia in preparation for surgery. Nimbex helps keep the body still during surgery. Nimbex also relaxes the throat so a breathing tube can be more easily inserted before surgery. Nimbex is available in generic form. Common side effects of Nimbex include:
- mild itching or skin rash, or
- flushing (warmth, redness, or tingly feeling under the skin).
Tell your doctor if you have serious side effects of Nimbex including:
- slow heart rate,
- noisy breathing,
- shortness of breath,
- ongoing muscle weakness, or
- inability to move your muscles.
Dosage of Nimbex is individualized based on the patient's condition, weight and other factors. Nimbex may interact with lithium, seizure medications, heart rhythm medications, tetracycline antibiotics, or an aminoglycoside. Tell your doctor all medications you use. Tell your doctor if you are pregnant or plan to become pregnant during treatment with Nimbex. It is unknown if this medication passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.
Our Nimbex (cisatracurium besylate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you feel numb or have loss of movement in any part of your body.
Common side effects may include:
- slow heart rate;
- dizziness; or
- flushing (warmth, redness, or tingly feeling).
Read the entire detailed patient monograph for Nimbex (Cisatracurium Besylate Injection)
Clinical Studies Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Adverse Reactions In Clinical Trials Of NIMBEX In Surgical Patients
The data presented below are based on studies involving 945 surgical patients who received NIMBEX in conjunction with other drugs in US and European clinical studies in a variety of procedures [see Clinical Studies].
Table 3 displays adverse reactions that occurred at a rate of less than 1%.
Table 3. Adverse Reactions in Clinical Trials of NIMBEX in Surgical Patients
Adverse Reactions In Clinical Trials Of NIMBEX In Intensive Care Unit Patients
The adverse reactions presented below were from studies involving 68 adult ICU patients who received NIMBEX in conjunction with other drugs in US and European clinical studies [see Clinical Studies]. One patient experienced bronchospasm. In one of the two ICU studies, a randomized and double-blind study of ICU patients using TOF neuromuscular monitoring, there were two reports of prolonged recovery (range: 167 and 270 minutes) among 28 patients administered NIMBEX and 13 reports of prolonged recovery (range: 90 minutes to 33 hours) among 30 patients administered vecuronium.
The following events have been identified during post-approval use of NIMBEX in conjunction with one or more anesthetic agents in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to NIMBEX: anaphylaxis, histamine release, prolonged neuromuscular block, muscle weakness, myopathy.
Read the entire FDA prescribing information for Nimbex (Cisatracurium Besylate Injection)
© Nimbex Patient Information is supplied by Cerner Multum, Inc. and Nimbex Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.